PostEra
postera.ai
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
PostEra uses machine learning for medicinal chemistry, proposing synthesis routes and analogues for drug discovery programmes. Founded in 2019 by Cambridge chemists, it coordinated the open science COVID Moonshot antiviral project. The company partners with major pharmaceutical firms on generative chemistry.
News
How PostEra designs drugs from code
The start-up is making antivirals and cancer drugs for Big Pharma-and working to treat reproductive problems on its own
Read more
Report
PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine learning for Drug Discovery
--PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery, today announced a strategic partnership with Pfizer Inc. with the goal of accelerating small molecule drug discovery by developing a platform tec
Read more
Report
PostEra COVID-19
An international effort to discover a COVID antiviral. Scientists share drug designs, and our cutting-edge machine learning tools determine which to test.
Read more
Report
Pro access
Upgrade to see all 6 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.